Hengxu Capital Establishment
Successfully raised 5 billion -scale Yangtze River Delta Fund
Hengxu Capital is a market-oriented private equity company with strong industrial background.
Hengxu Capital, founded in 2019, is a market-oriented private equity company with strong industrial background. Our management team comprises seasoned professionals from diverse fields, who have delivered outstanding and sustainable fund performance through their extensive industry expertise and exceptional investment capabilities. Our equity investment team focuses on technology, healthcare and consumer sector, and other opportunities aligned with China's economic transformation and new quality productive forces. We prioritize five key investment themes: Factor Innovation, Product Upgrading, Technology Spillover, Disruptive Innovation, Demographic Shifts. Our alternative investment team focuses on merger-and-acquisition opportunities of high-quality assets in the fields of wind power, photovoltaics, energy storage, charging and other new energy infrastructures, with a commitment to delivering sustainable and stable returns for investors. Our invision is to enable investors to achieve substantial returns while promoting the synergistic development of environmental, social, and governance (ESG) aspects. Our goal is to become a leading industrial capital and trusted top-tier investment institution.
History
The first investment company Aibo Medical successful IPO
Winning investment list · China's best private equity investment institution top100
Winning China · Best Private Equity Investment Institution TOP100
The management scale exceeds 20 billion
Winning Qingke List · China Private Equity Investment Institution TOP100
The management scale exceeds 30 billion
Private equity investment fund manager selected for insurance fund investment evaluates the list of class A
The first primary fund based on household photovoltaic power stations has completed registration and filing on AMAC
Four new energy asset acquisition funds
have been successfully established, with a total size exceeding 1.5 billion
Portfolios
上海芯旺微电子技术有限公司
基于自主研发的 KungFu指令集和内核架构，研发高性能数模混合信号MCU&DSP产品的芯片设计公司，同时向用户提供完整软硬件工具链系统，实现了从MCU芯片到基础软件生态的全覆盖。
https://www.chipon-ic.com/AboutUs/Index
德美联合（重庆）医疗科技有限公司
德美联合（重庆）医疗科技有限公司（简称“德美医疗”）是一家集运动医学植入物、手术工具、关节镜设备、运动康复器具和设备的研发、生产、销售、服务于一体的国际化医疗科技集团。
http://www.deltamedical.cn/
浙江老鹰半导体技术有限公司
浙江老鹰半导体技术有限公司是一家从事新型半导体材料设计、研发及封装加工的国家高新技术企业。公司致力于高速光通信VCSEL芯片、高功率密度激光雷达VCSEL芯片、高效率3D感测VCSEL芯片以及新型LED封装产品的研发、生产和销售，全面赋能数据中心光互连、汽车自动驾驶与智能座舱、消费电子及工业应用的传感与智慧照明等领域，为行业客户提供领先的光解决方案。
www.zjeagles.com
爱博诺德（北京）医疗科技股份有限公司
爱博诺德（北京）医疗科技股份有限公司，科创板上市企业，位于北京中关村国家自主创新示范区，是国家级高新技术企业、国家级专精特新“小巨人”企业。公司专注于眼科医疗器械的自主研发、生产、销售及相关服务。
股票代码：688050.SH
http://www.ebmedical.com/about/#profile
北京晶品特装科技股份有限公司
公司主营业务为光电侦察设备和军用机器人系统的研发、生产和销售，主要产品包括多个型号系列的无人机光电吊舱、手持光电侦察设备、单兵夜视镜、手持穿墙雷达、排爆机器人、多用途机器人、便携式侦察机器人等。
股票代码：688084.SH
https://www.jp-tz.com/
News
2025年5月「企业动态」
恒旭资本带您回顾2025年5月企业动态
恒旭资本荣获PEAS「2024年度最佳投资机构」
近日，上海股权投资协会发布「2024股权投资年度榜单」。恒旭资本凭借优秀的投资业绩和深厚的产业影响力，荣获「年度最佳投资机构」，被投企业银河通用荣获「年度最佳投资案例」。
恒旭资本荣获2025未来医疗100强「创新赛道投资机构——特医食品」
5月9日，2025未来医疗100强榜单发布，恒旭资本荣获「创新赛道投资机构——特医食品」。
Company advantages
- Exceptional industrial background Access to Large-Scale, Scarce Project Resources Providing environment for business realization Large customer base
- Abundant and pragmatic resources Years resource accumulation in the industry Diverse and abundant investor resources Close relationship with intermediary and exchange
- Long-term dedicated and professional team Our core team has been working together over ten years Top level professionals from first-class institutions Self-driven, diligent and responsible attitude
- Efficient and compliant execution capabilities Efficient collaboration brought by market-oriented mechanisms Compliance awareness brought by state-owned company background Mature system honed over years of experience
Asset Management Association of China Registration Number：P1070270
Address：5th Floor, Building N3, New Bund Square City, No. 2, Lane 131, Qiantan Avenue, Pudong New District, Shanghai
Email：scir@hengxucapital.com
Follow us on WeChat
All rights reserved. Hengxu Capital
Shanghai ICP Filing Number 2021018213 Shanghai ICP Filing Number 2021018213
Asset Management Association of China Registration Number:：P1070270
Address：5th Floor, Building N3, New Bund Square City, No. 2, Lane 131, Qiantan Avenue, Pudong New District, Shanghai
Email：scir@hengxucapital.com
All rights reserved. Hengxu Capital
Shanghai ICP Filing Number 2021018213Shanghai ICP Filing Number 2021018213
Top
